This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. FDAapproval of the VENTANA MMR RxDx Panel provides clinicians with access to a fully automated, easy-to-use MMR test to identify patients who are eligible for therapy with JEMPERLI.
Recently, a network-based drug-screening platform has been developed to test FDA-approved drugs for Alzheimer’s disease (AD) using 1,300 iPSC-derived organoids from 11 sporadic AD patients. Pharmaceutics. Pharmaceutics. 502:327-332 (2013). Nature Neuroscience. 22:669-679 (2019). link] Giorgi C, et al. 12(3) (2023).
Professor in the School of Medicine in the Department of Molecular and Cellular Physiology, and in Neurology, Psychiatry and Behavioral Sciences at Stanford University, a 2013 Nobel Prize winner in Physiology/ Medicine, a Howard Hughes Medical Institute investigator, and Chair of CytoDel’s Scientific Advisory Board. “We Südhof, M.D.,
The sponsor is the pharmaceutical company conducting the trial. A: Working in a pharmaceutical company is the best way to learn this. The sponsor-initiated IND is conducted by a pharma company seeking commercial approval. A: This does not usually happen. I can think of no reason they would transfer this to another sponsor.
FDA addressed the expanding practice of drug compounding in 1992 by issuing a compliance policy guide that clarified that pharmacies which compounded products at certain scales, for certain purposes, or without FDAapproval were clearly operating “outside the bounds of traditional pharmacy practice.”
Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta ® (ofatumumab) — the first and only self-administered, targeted B-cell therapy for relapsing forms of MS (RMS )— Mayzent ® (siponimod) and Gilenya ® (fingolimod) . Atlas of MS 2013. Adv Studies Pharm.
Such a situation is commonplace in the clinical trial realm, in which investigational drug products which are not already FDAapproved are administered to patients. Through this program, the FDA can conduct periodic stability testing on select products and extend the labeled shelf life accordingly.
As with much of the pharmaceutical industry, VASCEPA revenue and prescription growth have been adversely impacted by the COVID-19 pandemic. Amarin Corporation plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health.
If FDAapproved, it will join other previously-approved “-gepant” drugs [ rimegepant ] and [ ubrogepant ] as an additional treatment alternative for patients with migraine, particularly those for whom traditional triptan therapy has proven ineffective. New Haven, CT. and > 300 mg/mL at lower pH pKa 4.8
Food and Drug Administration (FDA) approved drugs, macrocycles are used to combat a range of diseases, including cancer, viral, fungal and bacterial infections, neurodegenerative and autoimmune diseases. Drug Discovery Today , 18(13-14):659666, 2013. Pharmaceuticals , 16(7):996, 2023. Yusof I, Segall MD. Springer, 2019.
In 2024, the pharmaceutical company Gilead announced that a single injection of lenacapavir protected 96 to 100 percent of recipients from HIV for up to six months. Zidovudine showed promise against multiple HIV strains in cultured cells, and the Food and Drug Administration (FDA) approved it for human studies within five months.
Instead of highlighting the cognitive dissonance of the possibility that both of these theories of liability could be viable, we could be touting the creativity of the plaintiff lawyers trying different approaches to force pharmaceutical companies to play an unfun version of Simon Says.
As the DDL blog has previously reported , Michigan’s longstanding presumption of non-defectiveness applicable to FDA-approved drugs was recently repealed by the Michigan legislature in S.B. As this provision is newly applicable to FDA-approved products, it has not been tested by the courts on this issue. Cartridge Co. ,
Another of our posts quoted similar concerns raised by our clients in the pharmaceutical industry as the matter was being successfully appealed to the United States Supreme Court: The Fifth Circuit’s ruling threatens to stifle pharmaceutical innovation by disrupting industry’s reasonable investment-backed expectations. FDA , 715 F.3d
2023) (HHS cannot force pharmaceutical manufacturers to sell unlimited amounts of prescription drugs at a discount) ( here ). The FDA requires real science for warnings; thus it had not mandated any warning remotely resembling Prop 65. The G/N MDL was created in 2013 and mostly settled in 2016. Forest Pharmaceuticals, Inc.
Bexis’ amicus efforts this year in Mallory obviously came to naught, and we’ve had our own cases on this list before (see, e.g. , 2013-2 and 2021-10 ). That’s significant because the labels for over 500 drugs already have such information, under a voluntary FDA program. Takeda Pharmaceutical Co. , 3d , 2023 WL 4191651 (C.D.
FDA/Alliance for Hippocratic Medicine v. LLC litigation, in which an anti-abortion group is seeking to invalidate regulatory actions taken by the FDA with regard to mifepristone , a pharmaceuticalFDA-approved for use in the termination of pregnancy to ten weeks, in combination with misoprostol. FDA , 715 F.3d
Ortho-McNeil-Janssen Pharmaceuticals, Inc. , 2015), and the Supreme Court’s opinion in Mutual Pharmaceutical Co. 2466, 2471 (2013). It makes no difference in our view that the FDA ultimately approved TAF-based drugs. Gilead Sciences, Inc. , 18-cv-06972, 2023 WL 6390598, at *3 (N.D. 3d 281 (6th Cir.
2013), the court held that plaintiff could not “bring a claim that rests solely on the non-disclosure to patients of facts tied to the scope of [FDA] approval.” Finding non-disclosure different than, for example, a claim premised on false assertions of FDAapproval. Nidek Co. , 3d 1109, 1119 (9 th Cir.
341 (2001), (2) impossibility preemption barring “stop selling” claims under Mutual Pharmaceutical Co. 472 (2013), and (3) express OTC drug preemption under 21 U.S.C. Food and Drug Administration (FDA)-approved drugs (both prescription and OTC) that are part of medication abortion and emergency contraception medical treatments.
in part to aid the cause of medical device and pharmaceutical manufacturers , targets in our lawsuit-obsessed country. 604 (2011), and Mutual Pharmaceutical Co. 472 (2013) is worth consideration as well. It is fair to say that Bexis co-founded this blog (in 2006!) 379r(a)(1). 379r(e) product liability savings clause Id.
The court dismissed the design-defect claim as pleaded, holding it impliedly preempted under Mutual Pharmaceutical Co. 472 (2013), because “[i]t would be impossible for [the manufacturer] to comply with both its state duty to change the composition of [the biologic] and its duty under 21 C.F.R. Bartlett , 570 U.S. Courts are divided.
472 (2013). Since the appellate decisions in Wimbush and Lance , few courts have expressly recognized a “stop selling” cause of action for FDA-authorized medical products. But sue she did, so Beaver ends up as another case rejecting the silly stop selling theory of liability for an FDA-approved drug. Mensing , 564 U.S.
Novartis Pharmaceuticals Corp. , 2013); Massa v. Luitpold Pharmaceuticals, Inc. , Texas, unlike most states, enforces a strong statutory presumption that prescription medical product warnings complying with FDA requirements imposed by “pre-market approval or licensing of the product” are adequate as a matter of law.
2019), or Mutual Pharmaceutical Co. 472 (2013), implied preemption decisions, cited only by the dissent in Wyeth v. Plaintiffs Legal Committee , 531 U.S. Kent , 552 U.S. 440 (2008) Buckman was not cited at all in the Merck Sharp & Dohme Corp. Albrecht , 139 S. Bartlett , 570 U.S. Levine , 555 U.S. 555 (2009), and rated only a “ cf.
June 24, 2022), we fully expect attempts by such states to ban FDA-approved prescription drugs that can be used to bring about abortions by chemical means. But when the FDA has approved a product, states no longer have the power to prohibit their sale or use for FDA-approved indications. 627, 636 (2013).
2012), addressed a challenge to the application of Idaho’s Pain-Capable Unborn Child Protection Act to criminalize the use of an FDA-approved abortifacient medication obtained through an internet prescription and mailed to the plaintiff from out of state. 472 (2013). (See As we discussed here , McCormack v. Hiedeman, 694 F.3d
Mutual Pharmaceutical Co. 2466, 2475 (2013). In concluding plaintiff plausibly alleged a design defect, the court relies heavily on the “nearly 600” adverse events reported to the FDA — creating a classic case of damned if you do, damned if you don’t. Bartlett , 133 S.
Just as the previous Fosamax MDL judge had back in 2013, the current Fosamax MDL judge found all of the plaintiffs’ claims (only warning claims appear now to be at issue) preempted – only this time as a matter of law under Albrecht. 604 (2011), and Mutual Pharmaceutical Co. 472 (2013), apply to prescription drug preemption as well?
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content